Bepi Dispenser Set to Revolutionize Hospital Drug Delivery After Successful Crowdfunding

After having concluded the equity crowdfunding campaign on the Mamacrowd portal, with a collection of over 460,000 euros which exceeded the goal of 400,000 Bepi Dispenser is ready to land on the market this autumn, with mass production.

The company in fact declares that, starting next October, 100 Bepi Dispensers will be placed in hospitals by the end of 2025.

Bepi Dispenser is the first automatic dispenser of medicines at the hospital patient’s bedside designed and developed entirely in Italy by a team with over twenty years of experience in the healthcare, technological and managerial fields.

The product was born from the need to address the shortcomings of the nursing system of the most advanced countries, identifying an automated solution to improve the efficiency of drug administration.

Bepi Dispenser wil be tested in Habilita clinics

While waiting for the market launch, Bepi Dispenser will be tested for the next two months in the Bergamo and Acqui Terme (Alessandria) facilities of the Habilita group, a network of clinics for sports rehabilitation, neurorehabilitation and orthopedic surgery.

“An important first test, preparatory to an official and widespread diffusion that will take place in the second half of the year” states Roberto Schibuola , CEO and co-founder of Bepi, together with Nicola Abbattista, Marco Scardino and Francesco Tasso.

“We are finalizing agreements with hospitals throughout Italy and have signed contracts with medical equipment distributors. We plan to place 100 Bepi robots on the market by 2025, 900 by 2026 and 2000 by 2027, ” continues Schibuola.

How the funds raised will be invested

The funds raised for the Bepi Dispenser in the recent equity crowdfunding campaign on Mamacrowd, supported by Over Ventures, the European “crowdfunding studio” founded by Giancarlo Vergine, will be used immediately to purchase nine molds to produce eleven custom-designed components and for research and development expenses.

Over the past two years, the company has raised another €800,000 from equity funding (not crowdfunding) and participation in the “Silver Accelerator” acceleration program, 75% financed by CDP Venture, and has received funding through a ERDF call from the Liguria Region and the Smart&Start call from Invitalia.

The features of Bepi Dispenser

The Bepi Dispenser has a capacity of 60 pills, enough to manage the therapy for the entire duration of the hospital stay for most patients and allows the addition or modification of the drugs in real time; only authorized personnel can load the pills, thanks to a protected and tracked access system.

At the scheduled time, Bepi automatically dispenses the prescribed dose, alerting the patient with light and sound signals. The dispenser is configured by importing medical prescriptions from the patient’s electronic medical record or via a dedicated tablet.

Integration with electronic medical records used in healthcare facilities allows for centralized and automated management of therapies.

Bepi’s business model, for which two patents have been filed and are in the process of being released, is based on the association between the dispenser and the patient via a bracelet, while the machine is provided on loan for use, with invoicing calculated on the actual use (i.e. on the single patient).

__

(Featured image by Lance Reis via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.